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Abstract
While enhancers for embryonic stem cell (ESC)-expressed genes and lineage-determining factors 
are characterized by conventional marks of enhancer activation in ESCs1,2,3, it remains unclear 
whether enhancers destined to regulate cell-type-restricted transcription units might also have 
some currently overlooked, distinct signatures in ESCs. Here, we report that cell-type-restricted 
enhancers, are unexpectedly premarked and activated as transcription units by the binding of a 
single, or two, ESC transcription factors, although not exhibiting traditional enhancer epigenetic 
marks in ESCs, thus uncovering the initial temporal origins of cell-type-restricted enhancers. This 
premarking is required for future cell-type-restricted enhancer activity in the differentiated cells, 
with the strength of the ESCs signature being functionally important for subsequent robustness of 
cell-type-restricted enhancer activation. This model has been experimentally validated in 
macrophage-restricted enhancers and neural precursor cells (NPCs)-restricted enhancers using 
ESCs-derived macrophages or NPCs, edited to contain specific ESC transcription factor motif 
deletions. The ESC transcription factor-determined DNA hydroxyl-methylation of the enhancers 
in ESCs may serve as a potential molecular memory for subsequent enhancer activation in the 
mature macrophage. These findings suggest that the massive repertoire of cell-type-restricted 
enhancers are essentially hierarchically and obligatorily “premarked” by binding of a defining 
ESC transcription factor in ESCs, dictating robustness of enhancer activation in mature cells.
Enhancers function as critical regulatory elements that integrate genomic information for 
cell fate transition and cell specific gene regulation1,2,3. Here, we hypothesize that cell-type-
restricted enhancers might be premarked in ESCs. To begin to explore this question, we 
selected macrophage enhancers, because the sequential events leading to macrophage 
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differentiation and regulation by inflammatory signals are rather well understood4,5,6. We 
first examined the full repertoire of macrophage-restricted enhancers in ESCs, finding that 
the majority (18,405) exhibited an absence of H3K4me1, H3K4me2, H3K27Ac and 
H3K27me3 marks (referred to as “unmarked” in Extended data Fig.1a), although ~4,000 
enhancers, active in both macrophages and ESCs and including “housekeeping genes”, did 
exhibit H3K4me2 and H3K27Ac, generally within 200kb of coding target genes (Extended 
data Fig.1a, Fig.1a). Finally, a small number of enhancers (214) had marks of “poised” 
enhancers, i.e. H3K27me3 (Extended data Fig.1a, Fig.1a). To further understand the 
enhancer features in ESCs, an ATAC-seq assay was performed. The 18,405 “unmarked” 
macrophage enhancers were in an “open” configuration compared to random regions (Fig.
1b), consistent with published DNase hypersensitivity analyses in ESCs (Fig.1b), but not as 
robustly accessible when compared to ESC-active enhancers (Extended data Fig.1b). To 
more specifically identify the transcription factors (TFs) that might underlie the macrophage 
enhancers have an “open” chromatin configuration, we profiled the distribution of several of 
the most important ESC TFs - Esrrb, Nanog, Oct4 and Sox2 (ENOS) in a −1kb/+1kb 
window, ensuring that we were exclusively analyzing macrophage-restricted enhancers. 
Interestingly, we observed the binding of ENOS in 6,775 macrophage-restricted enhancers 
(Fig.1c). The specificity of ENOS binding in macrophage-restricted enhancers was 
established by comparing with random regions (Extended data Fig.1c), revealing a 
statistically significant binding of Esrrb (see example, Extended data Fig.1d). Interestingly, 
we found that ~80% of macrophage-restricted enhancers were bound by a single, or at most 
two, ESC TFs, while ESC-active enhancers exhibited binding of all four ENOS factors (Fig.
1d, Extended data Fig.1e), exemplified by genome browser images (Extended data Fig.1f). 
Premarking events were further studied by analyzing 12 ESC TFs from the published 
literature7, and finding that active ESC-restricted enhancers were characteristically bound by 
predominantly 4~8 of the 12 ESC TFs evaluated (Oct4, Sox2, Nanog, Esrrb, Smad1, E2f1, 
Tcfcp2l1, Zfx, Stat3, Klf4, c-myc and n-myc), consistent with their often-reported 
cooperative binding7,8, while the majority of the active macrophage-restricted enhancers 
exhibit binding of only one or two of these factors (Fig.1e).
To determine whether cell-type-restricted enhancers in other cell types also exhibit similar 
pre-marking, we examined cell-type-restricted enhancers from heart, kidney and N2A 
neuronal cells, finding that these enhancers in ESCs again predominantly exhibited binding 
of a single ENOS factor and chromatin openness (Extended data Fig.2a–d).
Given the well-established role of the Cohesin complex in chromatin architecture and gene 
regulation9,10,11, we examined whether the Cohesin complex plays a role in premarked 
enhancers, and found that Cohesin was colocalized with ENOS-bound regions (Fig.2e), 
consistent with previous report11. Therefore, next, it was important to investigate whether 
premarked enhancers could interact with other genomic regions. A macrophage enhancer 
located in 5’ of Il1a was selected and 4C-seq was performed12. This “premarked” enhancer 
exhibited specific interactions with other genomic regions in ESCs, including an upstream 
CTCF-bound site, but not with the cognate promoter. In Kdo2-lipid A (KLA)-treated 
macrophages, this enhancer exhibits robust interactions with the cognate promoter of the 
target coding gene (Extended data Fig.3a). An enhancer located in 5’ of Tnfaip3 was 
similarly found to exhibit specific interactions with other genomic regions in ESCs, but not 
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with its cognate promoter (Extended data Fig.3b). In addition, we performed RNA-seq and 
examined proximal macrophage-expressed genes of 6,775 macrophage-restricted enhancers, 
finding 634 differentially expressed genes (FC≥4), which correspond to functional 
categories relevant to the macrophage but not ESCs (Extended data Fig.3c,d). These data, 
together with 4C-seq, suggest that premarked macrophage enhancers are not functional, 
despite ESC TF binding and open chromatin configurations in ESCs.
To further explore any potential impact of ENOS binding in ESCs on the subsequent 
function of enhancers bound by Pu.1, a key macrophage TF, we assessed the physical 
location of ENOS binding in premarked enhancers. When centered on Pu.1 binding sites, we 
observed that the ENOS binding varies in the 6,775 macrophage enhancers, corresponding 
to the location of cognate binding sites (Fig.2a).
Because eRNA expression is a mark of enhancer activity13, the possibility of transcription 
unit in ENOS-bound premarked enhancer was examined. Because the GRO-seq data was 
insufficiently robust on these enhancer regions to draw clear conclusions, we performed 
PRO-cap. 2,336 of significant Cap sites were identified in −1kb/+1kb window in 6,775 
premarked enhancers in ESCs. While Cap sites were found to be located in close proximity 
to the Pu.1 binding site in the macrophages, they were located broadly in ESCs, at various 
distances from the Pu.1 site, correlating closely with ENOS binding sites (Fig.2b). The 
median distance from the Pu.1 site to the macrophage specific eRNA Cap (−500bp/+500bp 
from the Pu.1 site) proved to be ~105 bp in the mature macrophage13, while the median 
distance from the ENOS binding site to the ESC specific eRNA Cap was ~165 bp (Fig.2c). 
This ESC-induced transcription unit for each enhancer was therefore distinct from the eRNA 
transcription units subsequently nucleated by Pu.1 and C/EBPα in the mature macrophage, 
the binding sites for which are located within a “core” enhancer region. Indeed, ATAC-seq 
revealed chromatin openness in the region where ENOS bound to the enhancers (Fig.2d). 
The functional correlation between Cohesin and ENOS bound enhancers were further 
examined, and found that high Rad21 binding was associated with high ENOS binding and a 
more “open” configuration (Fig.2f).
To preclude any concerns regarding serum culture conditions, we performed ChIP-seq with 
H3K4me2 and H3K27Ac, and ATAC-seq under two different culture conditions: 2i and 
serum. H3K4me2 and H3K27Ac were not observed in macrophage enhancers in both 2i- 
and serum- cultured ESCs, and ATAC-seq signal was equivalently detected in both 
conditions (Extended data Fig.4a,b), indicating that culturing ESCs in serum did not impact 
our observations. Indeed, most pluripotency-associated genes were transcribed at similar 
levels in serum- or 2i- cultured ESCs14 and only 8% of cells are heterogeneous in serum-
treated ESCs15.
To investigate potential function of premarking, we examined the correlation between ENOS 
factors and the ultimate activity of the enhancers in the mature macrophage. ENOS-bound 
macrophage enhancers with the highest or lowest ~20% levels of ENOS transcription units 
were selected to test their ultimate activation in the macrophage. The highest group of 
enhancers exhibited the higher “activation”, as determined by binding of Pu.1, PRO-cap 
signal, eRNA transcription, levels of H3K4me2 and H3K27Ac, and binding of Cohesin in 
Kim et al. Page 3
Nature. Author manuscript; available in PMC 2018 October 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
macrophage (Fig.3a–d). In addition, when the highest or least ~20% of active macrophage 
enhancers were extracted based on GRO-seq signal in macrophage13, ENOS binding and 
ATAC-seq signals in ESCs proved to be higher in the most active macrophage enhancers 
compared to less active macrophage enhancers (Fig.3e,f). Indeed, we observed that 
putatively active macrophage enhancers, defined by eRNA transcription, are found much 
more frequently in the 6,775 ENOS-bound enhancers compared to the rest of the 11,630 
macrophage enhancers that do not bind ENOS in a −1kb/+1kb window (Fig.3g). The 
correlation between premarking and enhancer robustness was confirmed in other tissues: 
spleen, lung, cortex and bone marrow (Extended Data Fig.5a–d).
We next investigated whether the binding of these factors in ESCs exerted a direct role on 
the ultimate activation of the cell-type-restricted enhancers in the mature macrophage, 
choosing premarked macrophage-restricted enhancers linked to coding target genes that 
would not be predicted to influence macrophage development. We first selected a putative 
enhancer near the Tlr1 locus, and then used CRISPR-Cas9 technology in ESCs to selectively 
delete the Esrrb binding site, followed by differentiation16 (Extended data Fig.6b). Mature 
macrophages were selected based on their ability to adhere to the non-adherent culture 
plates, as confirmed by expression of Cd11b and F4/80 (Extended data Fig.6a), permitting 
only a limited harvest of mature macrophages, thus precluding global genomic analyses. 
Significantly, three independently-derived individual clonal lines (#3, #10, #14) were 
sequence-proven to harbor a 8 bp deletion of the Esrrb site in the Tlr1 enhancer (Extended 
data Fig.6c,d). Consistent with the confirmed deletion, Esrrb binding in ESCs was decreased 
in these mutant clones compared to wild type (wt) clones (Fig.4a). The mutant clonal cells 
were differentiated to macrophages with an equivalent efficiency with the wt cells; ChIP-
qPCR for Pu.1 and H3K4me2 was performed, and eRNA transcription was measured in the 
ESC-derived macrophages (ESDM). These analyses revealed that Pu.1 binding was 
inhibited, that eRNA transcription was lost, and that there was a consistent decrease in the 
level of the H3K4me2 with deletion of the Esrrb site (Fig.4b). To corroborate these findings, 
mutant clonal cells targeting another enhancer, Tnfaip3 enhancer, were constructed with 
either a 16 bp deletion (#26) or a 21 bp deletion (#45) encompassing the Esrrb binding site 
(Extended data Fig.6e–g), and differentiated to macrophage, finding that the reduction of Pu.
1 recruitment, eRNA transcription and H3K4me2 levels in mutant ESDM correlated with 
inhibition of Esrrb binding in ESCs (Fig.4c,d). As a control, we tested Tlr1 eRNA 
transcription in Tnfaip3 mutant cells, observing no change (Extended data Fig.6h). As 
additional tests, two other loci, Prdx5 and Nod2, were similarly investigated (Extended data 
Fig.7a–b,e–f), again finding that enhancer activities defined by eRNA transcription were 
inhibited in mutant ESDM with loss of Esrrb binding in ESCs, but Prdx5 mutant enhancers 
(B11, F1, G11) exhibited the same level of Nod2 eRNA transcription as wt (Extended data 
Fig.7c–d,g). Because modifying the genomic locus could potentially result in different 
genetic events, we performed RNA-seq in the Tlr1 enhancer clonal cells (wt, #10, #14), 
finding that normal ESCs and clonal ESCs (wt, #10 and #14) exhibited the same pattern of 
transcription in the Tlr1 loci (Extended data Fig.6i).
Enhancers harboring the Esrrb core site deletion were evaluated by luciferase reporter assay 
for any potential impairment of enhancer function compared to the wt enhancers in 
macrophage due to genomic sequence disruption, finding that it was equally competent to 
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increase reporter expression as the wt enhancer in immortalized Raw 264.7 macrophage 
cells (Fig.4e), further evidence that inhibition effects in Tlr1 mutant ESDMs is due to 
inhibition of Esrrb binding in ESCs.
This functional linkage was further examined in neural precursor cell (NPC)-restricted 
enhancers, selecting enhancers in the Nek1 or Ankrd1 loci, referred to as N4 or N8, 
respectively. Sox2 and Esrrb binding in N4 and Esrrb binding in N8 were found, and Sox2 
or Esrrb binding site, in N4 or N8, respectively, was targeted for deletion (Extended data 
Fig.8a,d). Clonal ESCs were differentiated to NPCs in N2B27 medium for 6 days, with 
>70% cells exhibiting the green signal caused by Sox1-GFP reporter knocked-in in ESCs17. 
NPC differentiation was further confirmed by qRT-PCR with ESC-specific genes (Oct4, 
Esrrb and Nanog) and NPC-specific genes (Sox1, FGF5, Nestin and Pax6) (Extended data 
Fig.8g). The eRNA transcription of N4 or N8 was inhibited in N4- or N8- mutant ESC-
derived NPCs, respectively correlating with inhibition of Esrrb binding in ESCs (Extended 
data Fig.8b,e). Sox2 binding could not be assessed due to ineffectiveness of the anti-Sox2 
IgG. The specificity of N4- or N8-mutant clones on inhibition of eRNA transcription was 
confirmed by testing eRNA transcription in the N8 locus in N4 mutant cells; or the N4 locus 
in N8 mutant cells (Extended data Fig.8c,f).
Collectively these analyses corroborate the functional importance of ESC factor premarking 
in both macrophage-restricted and NPC-restricted enhancers.
Poised enhancers, another class of well-studied cell-type-specific enhancers marked in 
ESCs, are often found near lineage-determining factors, often as super-enhancers18,19,20 
exemplified by Pu.1. The 214 macrophage enhancers exhibit poised chromatin signatures 
(Extended Data Fig.1a) with binding of 2~4 ENOS factors in the core of their enhancers in 
the ESCs (Extended Data Fig.9a,b). For example, we noted that the Pu.1 gene has four 
clustered enhancers with poised chromatin signatures in ESCs. In contrast to the two 
enhancers (Enh2 and Enh3) active in mature macrophages, the other two (Enh1 and Enh4), 
bound by Esrrb and Oct4, are not (Extended Data Fig.9c,d). These two premarked enhancers 
in ESCs might participate in the early activation of Pu.1, which is known to exhibit a 
positive feedback loop on the two Pu.1-bound enhancers21.
A particularly intriguing question is how the marking of future cell-type-restricted enhancers 
might be “remembered” for their ultimate activation later in development. Based on the 
literature and analysis of the mRNA levels of the ENOS factors, the temporal pattern of 
disappearance of these factors virtually coincides with the appearance of the first lineage 
determining factors, Tal1, Gata2 and RunX1, followed by the appearance of Pu.1 and C/
EBPα, which initiate macrophage enhancer activation program22 (Extended data Fig.10a). 
Another potential explanation is that binding of one of the ESC TFs on the future cell-type-
restricted enhancers might be accompanied by a specific DNA demethylation event that 
serves to ensure that an enhancer remains accessible to TFs, the binding of which may be 
impaired by DNA methylation. We therefore analyzed available data in ESCs regarding 
DNA methylation and, interestingly, we found the 5-hmC mark and the enzyme responsible 
for that mark, TET1, to be present in the 6,775 premarked macrophage enhancers (Fig.4f), 
reflecting the previous observation of the presence of TET1 in a complex with Esrrb and 
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Oct423. Interestingly, we further found that knockdown of Esrrb reduced 5-hmC levels in 
Esrrb-bound macrophage enhancers in ESCs (Extended data Fig.10b). To examine whether 
5-hmC is maintained during the differentiation process, such that it could serve as a marker 
for molecular memory, we examined 5-hmC during hematopoiesis using published data24, 
and found that the 5-hmC was maintained during hematopoiesis (Extended data Fig.10c, 
Fig.4g). The enhancer histone marks, H3K4me1 and H3K27Ac, were studied during 
hematopoiesis25, but not found in ESCs, or even in mesoderm, being gained gradually early 
in hematopoesis (Extended data Fig.10c,d).
Investigation of the signature of cell-type-restricted enhancers in ESCs has provided a 
surprising insight into the process of genomic enhancer recognition in ESCs underlying cell-
type-specific transcriptional programs. Furthermore, the marking of the cell-type-restricted 
enhancers in ESCs license the ultimate robust activation of the cell-type-restricted enhancer 
in the mature differentiated cell (Extended data Fig.10e).
METHODS
Cell culture
46c murine ESCs were kindly gifted by Austin Smith. Cells were grown in feeder free 
condition as previous described17. ESCs were maintained in serum culture medium with 
DMEM-KO(Invitrogen 10829-018) supplemented with 15% ESC qualified-fetal bovine 
serum (Omega, FB-05), 2 mM nonessential amino acids (Invitrogen 11140-050), glutamax 
(Invitrogen 35050061), penicillin/streptomycin (Invitrogen 15140122), 2-mercaptoethanol 
(Sigma, M7522) and 1000 U/ml LIF (ESGRO, ESG1106). ESCs in 2i medium were grown 
in N2/B27 media with 50% Neurobasal (Gibco 21103-049) and 50% DMEM/F12 
(Invitrogen 21331-020), 2 mM nonessential amino acids, glutamax, penicillin/streptomycin, 
2-mercaptoethanol, N2 supplement (Invitrogen, 175020-01), B27 (Invitrogen, 17504-001), 
1000 U/ml LIF, and 2i (ESGRO, ESG1121). Mycoplasma contamination was regularly 
checked (Lonza, LT07-318). Peritoneal macrophages were obtained from 6–8 weeks of 
female C57BL/6J mice obtained from Jackson laboratory. Mice were injected with 
thiogycollate 3–4 days before collecting day, and cultured in RPMI supplemented with 10% 
FBS and penicillin/streptomycin for overnight before collection. All animal care and 
experimental procedures were in accordance with the University of California, San Diego 
research guidelines for the care and use of laboratory animals.
Antibodies
Antibodies used for ChIP/ChIP-seq included: Rad21 (Abcam, ab992), H3K4me2 (Upstate, 
07-030), Pu.1 (Santa Cruz, sc-352) and H3K27Ac (Active Motif, 39133); for immuno-
staining, F4/80-FITC (eBioscience, 11-4801-81) and CD11b-PE-Cyanine5 (eBioscience, 
15-0112-81); for MeDIIP, 5-hmC (Active Motif, #39769).
Enhancer reporter assay
For construction of Tlr1 enhancer reporter plasmids, 600bp of Tlr1 locus spanning the Esrrb 
binding site was PCR amplified and cloned into pGL4.23 at the KpnI/XhoI sites downstream 
of the luciferase reporter gene controlled by a minimal promoter. Enhancer reporters were 
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transfected into RAW264.7 macrophages using Lipofectamine 3000 (Invitrogen), using 200 
ng of enhancer reporter and 5 ng of Renilla. Luciferase activity was measured 48 h after 
transfection using a Veritas microplate luminometer (Turner Biosystems) and normalized to 
Renilla activity to correct for differences in transfection efficiency. Experiment was 
performed five independent times. In the box plots, line shows median, and box shows 25th 
and 75th percentiles. P-values are calculated using Welch’s two t-test.
ESC differentiation to macrophage
ESC differentiation to macrophage was performed as described previously16. In brief, ESCs 
were trypsinized and transferred to bacteriological plates in macrophage differentiation 
medium A which has 15% L929 conditioned medium and 1ng/ml IL3 but lack of LIF for 
6~8days to make embryoid bodies (EBs). EBs were transferred onto gelatin-coated tissue 
culture dishes for 3~4 days. After that, supernatants of adherents EBs containing floating 
macrophage progenitors were collected and plated onto bacteriological dishes for 7 days to 
obtain adherent macrophage in macrophage differentiation medium which has 15% L929 
conditioned medium. Medium was readded to the adherent EB plates and macrophage 
progenitors were obtained every 2 days.
ESC differentiation to NPCs
ESC differentiation to NPCs was performed as described previously17. Briefly, ESCs were 
trypsinized, plated in gelatin-coated plates and cultured in N2B27 medium for 6 days. On 
Day6, >70% of green-signal expressing cells were observed, which indicates differentiation 
of NPCs, and cells were collected for further experimental analysis.
CRSIPR/Cas9 assay
The online software (http://crispr.mit.edu) was employed to design optimal candidate 
sgRNAs to target proximal regions of ESC TF motif and these sgRNAs were cloned to 
vector PX459 (Addgene #48139), which co-expresses sgRNA and Cas9. This plasmid was 
transfected into ESCs with Lipofectamine 2000 and 1.0 µg/ml puromycin was added 2 days 
after transfection. Cells were cultured for another 3 days then diluted to pick up single-cell-
derived clonal lines. DNA was extracted from these cells and PCR was performed to amplify 
fragment containing sgRNA-targeted ESC TF (Esrrb or Sox2) motif. Sequencing was 
applied to identify Esrrb motif mutated/deleted clones. sgRNA sequences and primer 
sequences are listed in supplementary table 2.
RNA preparation and RT-qPCR
RNA was isolated using Trizol (Invitrogen) or RNeasy kit (Qiagen). RNA was reverse 
transcribed using SuperScript III Reverse Transcriptase kit (Invitrogen). Quantitative PCR 
was performed using SYBR Green Master Mix (Biorad). The experiments were repeated at 
least three times as biological replicates and P-values were obtained using Welch’s two t-
test. Primers are listed in supplementary table 2.
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RNA-seq
RNA-seq sequencing libraries were made from 1 µg of DNase-treated total RNA samples 
using TruSeq stranded mRNA Library Prep Kit (Illumina, RS-122-2101, RS-122-2102) and 
performed according to the manufacturer’s instructions. RNA-seq libraries were quantified 
with Qubit, clustered and sequenced using HiSeq 3000/4000 SR cluster kit (Illumina 
GD-410-1001) and HiSeq 3000/4000 SBS kit (Illumina FC-410-1001). RNA-seq reads were 
counted by HOMER software considering only exonic regions for RefSeq genes. The 
proximal macrophage-expressed genes of 6,775 macrophage-restricted enhancers were 
obtained by using these criteria: FC≥4, over 20 tags in macrophage, and visualized by 
heatmap with log2 transform. Gene ontology analysis and genetic association analysis was 
performed using Metascape (http://metascape.org).
PRO-cap
Pro-cap and library preparation for sequencing was described previously26. Nuclei were 
prepared from ~40 million cells for run-on assay. Run-on reactions were stopped and RNA 
was extracted with Trizol LS reagent (Invitrogen). Following DNase treatment, the RNA was 
fragmented. Biotin incorporated fragmented RNA was immunoprecipitated with anti-
strepavidin beads (Invitrogen). Then the RNA was treated with 3′-dephosphorylated using 
polynucleotide kinase (Enzymatics) and precipitated. The RNA was dephosphorylated with 
calf intestinal phosphatase (NEB) and 5′-de-capped with tobacco acid pyrophosphatase 
(Epicentre). The reaction was stopped and RNA was extracted with Trizol LS, and libraries 
were prepared by ligating Illumina TruSeq-compatible adapters to the RNA 3′ and 5′ ends 
with truncated mutant RNA ligase 2 (K227Q) and RNA ligase 1 (NEB), respectively, 
followed by reverse transcription, cDNA isolation and PCR amplification. Final libraries 
were size selected on TBE gels to 60–110 bp insert size. PRO-cap results were trimmed to 
remove A-stretches originating from the library preparation. Each sequence tag returned by 
the Illumina Pipeline was aligned to the mm9 assembly using Bowtie2 allowing up to 3 
mismatches. Only tags that mapped uniquely to the genome were considered for further 
analysis. Each sequencing experiment was normalized to a total of 107 uniquely mapped 
tags by adjusting the number of tags at each position in the genome to the correct fractional 
amount given the total tags mapped.
ChIP-seq
Cells were fixed with 2mM disuccinimidyl glutarate (DSG) (proteochem) for 45 mins and 
1% formaldehyde for 10 mins, and quenched by glycine for 5 mins. Nucleus lysates were 
prepared by using sonication buffer with 1% SDS, and immunoprecipitation was performed 
with several different antibodies. After overnight incubation with antibodies, beads we re 
added for another 3hrs, and washing was performed. Reverse-crosslinking was done for 
overnight at 65°C and DNA was purified using QIAquick Spin column (Qiagen). For ChIP-
seq, extracted DNA was ligated to adaptors and deep sequencing was performed with 
Illumina’s HiSeq 2000, 2500, or 4000 system according to the manufacturer’s instructions. 
The first 48bp for each sequence tag returned by the Illumina Pipeline was aligned to the 
mm9 assembly using BFAST or Bowtie2. Only uniquely mapped tags were selected for 
further analysis. The data was visualized by preparing custom tracks on the UCSC genome 
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browser using HOMER. Genomic binding peaks for transcription factor were identified 
using the findPeaks.pl command from HOMER with 8-fold enrichment over the input 
sample, 4-fold enrichment over local background, a minimal tag number of 16, and 
normalization to 107 mapped reads per experiment. For histone marks, initial seed regions of 
500bp were considered to calculate enriched reads. Regions of maximal density exceeding a 
given threshold with a FDR<0.001 were called as peaks. The peaks within ± 1,000bp apart 
from the RefSeq gene TSS site were considered to be promoter, and to focus the analysis on 
enhancers, peaks within 3kb of a gene promoter were filtered out.
4C-seq
Chromosome confirmation capture was performed as described previously12. Briefly, 10 
million cells were cross-linked with 1% formaldehyde for 10 min and quenched with glycine 
for 5 min on ice. Soluble chromatin was incubated with 400 U of HindIII (NEB) overnight 
at 37°C, and then intramolecular ligations were performed using 1000 U of T4 DNA ligase 
(NEB) for 4hr at 16°C under dilution. Chromatin was decrosslinked at 65°C and then treated 
with RNase to remove RNA before purification using several phenol and phenol-chloroform 
extractions and ethanol precipitation. The second restriction digestion was also performed 
overnight at 37°C, using 50 U of DpnII (NEB). DNA was ligated overnight and purified as 
before and ultimately using Qiagen columns and subjected to inverse PCR (Expand Long-
Range PCR system; Roche Diagnostics) using a first primer designed on the viewpoint near 
a HindIII site and a second outer primer designed beside the DpnII site. Both primers 
contained Illumina sequencing adapters and barcodes for multiplexing. PCR samples were 
purified using a Roche kit and quantified using a Qubit. We analyzed data using a 
bioinformatics pipeline previously described12.
MeDIP-Seq
Genomic DNA for hMeDIP was isolated from cells using Qiagen’s DNeasy Blood and 
Tissue Kit. Isolated genomic DNA was then fragmented to 100–300 bp through sonication 
using Diagenode’s Bioruptor platform and the size distribution was confirmed through gel 
electrophoresis. Barcoded adaptors for Illumina sequencing were added to 1µg of 
fragmented genomic DNA per experiment, using the NEBNext Ultra II DNA Library Prep 
Kit for Illumina, following manufacturer’s instructions. This protocol was stopped after 
adapter ligation and cleanup (and before any amplification steps), and the adapter ligated 
fragmented DNA was then used for hydroxy-methylated DNA pulldown. Denaturing, 
immune-precipitation, washing, and purification of hydroxy-methylated DNA were 
performed as described previously27, with the following modifications. One µl of 5-hmC 
antibody containing serum was used per IP reaction. Washing was done five times, with each 
wash for 15 minutes at 4°C. Next, DNA was eluted from beads using 200 µl digestion buffer, 
incubated overnight with Proteinase K at 50°C, and purified using Qiagen’s QIAquick PCR 
Purification Kit. Purified hydroxy-methylated genomic DNA was then further processed 
with NEBNext Ultra II DNA Library Prep Kit for Illumina at the step of PCR Enrichment of 
Adaptor Ligated DNA, as per manufacturer’s instructions, continuing with the entire 
protocol to prepare libraries for Illumina sequencing. Data was mapped to mm9 using 
Bowtie2 with standard settings and peaks were found by using MACS with default 
parameter.
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ATAC-seq
ATAC-seq was performed as described previously28. Nuclei were prepared from 50,000 cells 
and the transposition reaction was performed for 30mins at 37°C. DNA fragments were 
amplified by PCR, purified and deep sequencing was performed with Illumina’s HiSeq 
2000, 2500, or 4000 system according to the manufacturer’s instructions. ATAC-seq data 
was mapped to mm9 using Bowtie2 with standard settings. Tag directories with reads 
mapped to the mitochondrial chromosome filtered out were created. ATAC-seq peaks were 
identified using findPeaks.pl in HOMER with the settings: -style histone -size 75 -minDist 
75 -minTagThreshold 6 -L 8 -F 8. BED files were created from Tag directories using the 
HOMER package.
Deep-sequencing
For all ChIP-seq, RNA-seq, 4C-seq, ATAC-seq, MeDIP-seq and PRO-cap, the DNA libraries 
were sequenced for 50cycles on Illumina’s HiSeq 200, 2500 or 4000 system according to the 
manufacturer’s instructions. Sequencing experiments were visualized by preparing custom 
tracks for the UCSC Genome browser.
Bioinformatic characterization of enhancers
The criteria for identifying Pu.1-H3K4me2 co-bound enhancer regions was that the distance 
from the center of a Pu.1 peak to the H3K4me2 peak-occupied region was ≤1kb. ESC factor 
bound macrophage enhancers were defined by calculating the distance ≤1kb between ESC 
factor peak spanning region and Pu.1 bound macrophage enhancers. The active ESC 
enhancers or active macrophage enhancers were defined using H3K27Ac (over 100 tags) to 
examine 12 different ESC factor binding. The functional macrophage enhancers were 
defined using GRO-seq (over 20 tags) in macrophage, and these enhancers were used to 
count number of functional enhancers in ENOS bound enhancer or non-bound enhancer in a 
−1kb/+1kb. Highly active or less active macrophage enhancers were created after excluding 
non-active macrophage enhancers by using GRO-seq (less than 5 tags) in macrophage. The 
comparison of tag intensity of ChIP-seq, ATAC-seq, PRO-cap and GRO-seq or distances 
between different categories were presented as boxplots by using normal scales. P-values 
were calculated using Welch’s two t-test. To profile the distribution of ESC factors 
surrounding Pu.1-H3K4me2 co-bound enhancer regions, ChIP-seq signals surrounding Pu.1 
peak centers were separated by 40 bins, and then were sorted by the tag numbers based on 
the distance to Pu.1 peak center.
GEO Data
The GEO data sets used in this study are listed in Supplementary Table 1.
Data availability
All deep sequencing data is deposited in GEO under accession number GSE81681.
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Extended Data
Extended data Figure 1. Features of macrophage-restricted enhancers in ESCs
a, Pu.1+, H3K4me2+ macrophage enhancer profiles in murine ESCs. b, Normalized tag 
counts of ATAC-seq and DNase-seq in 18,405 random regions vs. 18,405 macrophage 
enhancers vs. 28,450 ESC enhancers. c, The percentage of macrophage enhancers or random 
region bound by ENOS in a −1kb/+1kb window d, Esrrb binding in random regions vs. 
macrophage enhancers vs. ESC enhancers in ESCs. e, ENOS binding profiles in 6,775 
macrophage enhancers. f, UCSC genome browser screen shots show ENOS binding with 
chromatin openness but no enhancer marks, such as H3K4me2 and H3K27Ac in 
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macrophage-restricted enhancers in ESCs. The Irg1 gene locus has two different 
macrophage-restricted enhancers bound by ESC TF. The blue bar indicates macrophage-
restricted enhancers. In the box plots, line shows median, and box shows 25th and 75th 
percentiles. P-values are calculated using Welch’s two t-test.
Extended data Figure 2. ESC TFs bind in heart-, kidney-, N2A- restricted enhancers in ESCs
a, Profiles of cell-type-restricted enhancers in heart, kidney, and N2A neuronal cells, with 
percent of unmarked, poised and active enhancers in ESCs. b, Target percentage of ENOS 
bound heart-, kidney- and N2A-restricted enhancers in ESCs. c, Heatmap of Esrrb, Nanog, 
Oct4 and Sox2 binding with −1kb/+1kb window, centered on each transcription factor in 
17,561 heart-, 14,242 kidney- and 12,027 N2A cells-restricted enhancers in ESCs. d, 
Heatmap of ATAC-seq with −1kb/+1kb window, centered on each transcription factor in 
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heart-, kidney- and N2A cells-restricted enhancers in ESCs. Data from published sources are 
listed in Supplementary Table 1.
Extended data Figure 3. The premarked macrophage-restricted enhancers do not interact with 
cognate target coding genes of macrophage in ESCs
a, b, 4C-seq in ESCs and macrophage. Primer sets for 4C are listed in Supplementary Table 
2. (a), 4C-seq analysis of the Il1a gene locus from the enhancer viewpoint in KLA-treated 
peritoneal macrophages or in ESCs. Black arrow represents the interaction frequency based 
on the trunc mean in 4 00kb window. Coordinate of macrophage putative enhancer in 5’ of 
Il1a is indicated with red box. (b), 4C-seq analysis of the Tnfaip3 gene locus from the 
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enhancer viewpoint in KLA-treated Raw 264.7 macrophages or in ESCs. Black arrows 
indicate interactions based on linear mean in 1Mb window. Red box indicates coordinate of 
putative Tnfaip3 enhancer and blue circle indicates Tnfaip3 promoter. c, Heatmap of 634 
closest macrophage expressed genes (FC≥4, over 20 tags in macrophage) of 6,775 
premarked macrophage enhancers in ESCs and macrophage. Color indicates normalized tag 
counts with log2 transform. d, Go-term analysis of 634 closest macrophage expressed genes.
Extended data Figure 4. Features of 6,775 macrophage enhancers in ESCs are not altered by 
different ESC culture medium, 2i- or serum
a, b, Heatmap of (a), H3K4me2 and H3K27Ac, and (b), ATAC-seq in 6,775 premarked 
macrophage enhancers and 28,450 ESC enhancers in 2i- or serum- cultured ESCs. It is 
centered on ENOS and visualized in a −1kb/+1kb window.
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Extended data Figure 5. ENOS binding correlates with future enhancer activities
a, b, c, d, Comparison of the ~10% “most” marked (high) and “least” marked (low) 
enhancers selected based on ENOS binding, and the level of H3K4me1 and H3K27Ac on 
these enhancers in the mature tissues- (a), Spleen (b), Lung (c), Cortex (d), Bone marrow. In 
the box plots, line shows median, and box shows 25th and 75th percentiles. Red dots indicate 
each value of H3K4me1 or H3K27Ac. P-values are calculated using Welch’s two t-test. Data 
from published sources are listed in Supplementary Table 1.
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Extended data Figure 6. Premarking in ESCs is required for robust future macrophage enhancer 
activation
a, Photomicrographs of macrophages differentiated from ESCs documented by F4/80 and 
CD11b staining. Scale bar=50 µM. b, Screenshot of the Tlr1 locus. The blue box 
corresponds to CRISPR/Cas9 target region. c, d, The putative Tlr1 enhancer mutant 
sequence diagram and DNA sequence documentation of several of the homozygous 
mutation clones, used for analysis. e, Screenshot of the Tnfaip3 locus. The blue box 
corresponds to CRISPR/Cas9 target region. f, g, The putative Tnfaip3 enhancer mutant 
sequence diagram and DNA sequence documentation of several of the homozygous 
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mutation clones, used for analysis. h, Tlr1 eRNA transcription was tested in wt and mutant 
clonal cells (#26, #45) of Tnfaip3 enhancer. One representative experiment is plotted (n=2 
biological repeats). i, UCSC genome browser shot image of RNA-seq in Tlr1 locus in 
normal ESCs and clonal mutant ESCs (wt, #10, #14). Primer sets are listed in 
Supplementary Table 2.
Extended data Figure 7. Premarking in ESCs is required for robust future macrophage enhancer 
activation
a, b, The putative Prdx5 enhancer mutant sequence diagram and DNA sequence 
documentation of several of the homozygous mutation clones, used for analysis. c, Three 
mutant clones (B11, F1, G11) of the putative Prdx5 enhancer decreased level of Prdx5 
eRNA transcription in ESDM (right). Each dot indicates one biological experiment (n=3 
biological repeats from two pooled different experiments. n=2 biological repeats from two 
pooled different experiments for B11). Esrrb binding in ESCs is a representative experiment 
(left) (n=2 biological repeats). d, Nod2 eRNA transcription was tested in wt and mutant 
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(B11, F1, G11) clonal cells of Prdx5 enhancer. One representative data is plotted (n=2 
biological repeats). e, f, The putative Nod2 enhancer mutant sequence diagram and DNA 
sequence documentation of several of the homozygous mutation clones, used for analysis. g, 
Two mutant clones (D2, D12) of the putative Nod2 enhancer decreased level of Nod2 eRNA 
transcription in ESDM (right). Each dot indicates one biological experiment (n=3 biological 
repeats from two pooled different experiments. n=2 biological repeats from two pooled 
different experiments for D12). Esrrb binding in ESCs is a representative experiment (left) 
(n=2 biological repeats). In the box plots, line shows median, and box shows 25th and 75th 
percentiles. P-values are calculated using Welch’s two t-test. Primer sets are listed in 
Supplementary Table 2.
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Extended data Figure 8. Premarking in ESCs is required for robust future NPC enhancer 
activation
a, The putative Nek1 enhancer, referred to as N4, mutant sequence diagram and DNA 
sequence documentation of several of mutation clones (N4C3, N4C16), used for analysis. b, 
Two mutant clones (N4C3, N4C16) of the N4 enhancer decreased level of N4 eRNA 
transcription in NPCs (right). Each dot indicates one biological experiment. A representative 
experiment for Esrrb binding in ESCs is presented (left) (n=3 biological repeats for N4C3, 
n=2 biological repeats for N4C16). c, N8 eRNA transcription was tested in N4 mutant 
clones (N4C3, N4C16) to show specificity of N4 mutant cells on inhibition of N4 eRNA 
transcription. A representative experiment is presented (n=2 biological repeats). d, The 
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putative Ankrd1 enhancer, referred to as N8, mutant sequence diagram and DNA sequence 
documentation of several of the mutation clones (N8C6, N8C12), used for analysis. e, Two 
mutant clones (N8C6, N8C12) of the N8 enhancer decreased level of N8 eRNA transcription 
in NPCs (right). Each dot indicates one biological experiment. Esrrb binding in ESCs is a 
representative experiment showing inhibition of Esrrb binding in Esrrb deleted N8 locus 
(left) (n=3 biological repeats). f, N4 eRNA transcription was examined to prove the 
specificity of N8 mutant cells on inhibition of N8 eRNA transcription. A representative data 
is presented (n=3 biological repeats). g, NPC differentiation was confirmed on day 6 after 
differentiation by testing expression of ESC-expressing genes and NPC-expressing genes. A 
representative experiment is presented (n=2 biological repeats). In the box plots, line shows 
median, and box shows 25th and 75th percentiles. P-values are calculated using Welch’s two 
t-test. Primer sets are listed in Supplementary Table 2.
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Extended data Figure 9. ESC TFs binding in poised enhancer
a, Profile of 214 macrophage enhancers, which have poised chromatin signatures in ESCs. b, 
ESC transcription factors (Oct4, Sox2, Nanog, Esrrb, E2f1, Tcfcp2l1, Zfx and Klf4) were 
analyzed in 129 macrophage enhancers to test binding of ESC TFs. These 129 macrophage 
enhancers were obtained based on the criteria; high H3K27me3 in ESCs and high H3K27Ac 
(over 20 tags) in macrophage. Data from published sources are listed in Supplementary 
Table 1. c, Schematic diagram of Pu.1 enhancers. d, Genome browser screenshot of the 
poised Pu.1 enhancers. Blue arrow indicates Esrrb binding region and red arrow indicates 
Oct4 binding region. Red box indicates four clustered putative Pu.1 enhancers.
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Extended data Figure 10. Establishment and maintenance of 5-hmC on premarked enhancers 
and proposed model
a, Esrrb, Oct4 and CEBP level is measured in four different time points through 
differentiation process from ESCs to macrophage. b, 5-hmC level in 6,775 premarked 
enhancers in sictrl vs. siEsrrb expressing ESCs. In the box plots, line shows median, and box 
shows 25th and 75th percentiles. P-values are calculated using Welch’s two t-test. c, 
Schematic of the hematopoietic differentiation stages25. d, H3K4me1 and H3K27Ac in 
6,775 premarked enhancers were analyzed during hematopoietic differentiation- ESC, 
mesoderm, LT-HSC, ST-HSC, MPP, CMP, GMP and macrophage-, and presented in 
heatmap with −3kb/+3kb window at the center of Pu.1. Data from published sources are 
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listed in Supplementary Table 1. e, Model of “premarked” lineage determining and terminal 
differentiation enhancer indicating that poised enhancers bind several ESC transcription 
factors, while the late-activated cell-specific enhancers are premarked based on binding of a 
single ESC transcription factor, causing chromatin opening, transcription of a ncRNA, and 
appearance of a 5-hmC mark in the area of the enhancer that may provide the molecular 
memory for what ultimately will be the Pu.1/C/EBPα core from which eRNAs will be 
transcribed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Features of macrophage enhancers in ESCs
a, Heatmap of H3K4me1, H3K4me2 and H3K27Ac, and p300 with −3kb/+3kb window, 
centered on Pu.1 in 18,405 macrophage-restricted enhancers in ESCs. b, Tag density of 
ATAC-seq and DNase-seq in 18,405 macrophage-restricted enhancers and random regions in 
mESC shows chromatin openness of macrophage-restricted enhancers in ESCs. c, Target 
percentage of ESC TFs (Esrrb, Nanog, Oct4, Sox2) bound macrophage-restricted enhancers 
with −1kb/+1kb from macrophage-restricted enhancers. d, ENOS factor binding centered on 
each ESC factors in 6,775 premarked macrophage-restricted enhancers and 28,450 active 
ESC-restricted enhancers in −1kb/+1kb window. e, The binding of 12 ESC TFs (Oct4, Sox2, 
Nanog, Esrrb, Smad1, E2f1, Tcfcp2l1, Zfx, Stat3, Klf4, c-myc and n-myc) in 6,809 active 
Kim et al. Page 25
Nature. Author manuscript; available in PMC 2018 October 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
macrophage-restricted enhancer and 8,209 active ESC-restricted enhancers defined based on 
H3K27Ac (over 100 tags) in −1kb/+1kb window. ChIP-seq Data from published sources are 
listed in Supplementary Table 1.
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Figure 2. ESC TFs bind to macrophage-restricted enhancers in ESCs
a, d, e, Heatmap of (a), ENOS binding (d), ATAC-seq (e), Rad21 and Smc1 in −1kb/+1kb 
window in 6,775 premarked macrophage enhancers is plotted relative to the location of the 
Pu.1 binding sites in the enhancers. a, Last panel shows corresponding binding sites of 
ENOS to the presence of the ENOS binding. b, 2,345 PRO-cap peaks identified in 
macrophages or ESCs in −1kb/+1kb window from 6,775 premarked enhancers are plotted by 
heatmap centered on Pu.1. c, Location of PRO-cap peak sites from Pu.1 in macrophage or 
from the ENOS in ESCs is calculated in 638 premarked macrophage enhancers, which has 
PRO-cap peaks in a −500bp/+500bp window from Pu.1 binding sites. f, ENOS binding and 
ATAC-seq signal in highest vs. lowest ~40% of macrophage enhancers selected based on 
Rad21 binding intensity in ESCs. In the box plots, line shows median, and box shows 25th 
and 75th percentiles. P-values are calculated using Welch’s two t-test.
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Figure 3. ESC TF binding is predictive of future enhancer activity
a, b, c, d, Comparison of the highest or lowest ~20% of enhancers selected based on ENOS 
binding and PRO-cap signal in ESCs, and the level of (a), H3K4me2 and H3K27Ac (b), 
PRO-cap and GRO-seq (c), Pu.1 d), Rad21 in the mature macrophage. e, f, Comparison of 
the highly or less ~20% of active macrophage enhancers selected based on GRO-seq signal 
of premarked macrophage enhancers in macrophage, and the level of (e), ENOS (f), ATAC-
seq in ESCs. g, The percentage of functional macrophage enhancers in 6,775 enhancers 
which have ENOS in a −1kb/+1kb window (premarked enhancers) vs. 11,630 enhancers 
which don't have ENOS in a −1kb/+1kb window (non-premarked enhancers). In the box 
plots, line shows median, and box shows 25th and 75th percentiles. P-values are calculated 
using Welch’s two t-test.
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Figure 4. Premarking in ESCs is functionally required for robust future enhancer activation
a, c, The binding of Esrrb in WT vs. mutant clones of (a), Tlr1 (#3, #10, #14) (c), Tnfaip3 
(#26, #45) in ESCs. One example of representative data is added (n≥2 biological repeats). b, 
d, Pu.1 binding, eRNA transcription, and H3K4m2 level in WT vs. mutant clones of (b), 
Tlr1 (d), Tnfaip3 in ESDM. Each dot indicates a biological experiment (n≥3 biological 
repeats from two pooled different experiments, n=2 biological repeats from two pooled 
different experiments for #45 for H3K4me2 ChIP-qPCR). e, Promoter activities in native 
full length Tlr1 enhancer response to WT vs. Esrrb deleted mutant in Raw264.7 cells (n=5 
biological repeats). f, Mapping of DNA methylation modification (5mC and 5hmC) and 
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binding of Tet1 in 6,775 premarked-macrophage enhancers in a −1kb/+1kb window by 
centered on Pu.1. g, 5-hmC in LSK, CMP and GMP in 6,775 premarked enhancers in −3kb/
+3kb window centered on Pu.1. In the box plots, line shows median, and box shows 25th and 
75th percentiles. P-values are calculated using Welch’s two t-test. Data from published 
sources are listed in Supplementary Table 1. Primer sets are listed in Supplementary Table 2.
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